DE69737293D1 - Nukleotidsequenz, die für eine flavinmonooxygenase kodiert, das korrespondierende protein, sowie deren verwendungen in diagnostik und therapie - Google Patents
Nukleotidsequenz, die für eine flavinmonooxygenase kodiert, das korrespondierende protein, sowie deren verwendungen in diagnostik und therapieInfo
- Publication number
- DE69737293D1 DE69737293D1 DE69737293T DE69737293T DE69737293D1 DE 69737293 D1 DE69737293 D1 DE 69737293D1 DE 69737293 T DE69737293 T DE 69737293T DE 69737293 T DE69737293 T DE 69737293T DE 69737293 D1 DE69737293 D1 DE 69737293D1
- Authority
- DE
- Germany
- Prior art keywords
- flavinmono
- oxygenase
- diagnostics
- therapy
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002773 nucleotide Substances 0.000 title abstract 2
- 101000953909 Streptomyces viridifaciens Isobutylamine N-hydroxylase Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 101000847334 Homo sapiens Dimethylaniline monooxygenase [N-oxide-forming] 2 Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000007170 pathology Effects 0.000 abstract 2
- 229920001184 polypeptide Chemical group 0.000 abstract 2
- 108090000765 processed proteins & peptides Chemical group 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 238000010367 cloning Methods 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
- C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9615032A FR2756845B1 (fr) | 1996-12-06 | 1996-12-06 | Sequence nucleotidique codant pour une flavine monooxygenase , proteine correspondante et composition destinee au diagnostic et a la therapie du glaucome |
| FR9615032 | 1996-12-06 | ||
| PCT/FR1997/002226 WO1998024914A1 (fr) | 1996-12-06 | 1997-12-05 | Sequence nucleotidique codant pour une flavine mono-oxgynase, proteine correspondante et leurs applications dans les domaines du diagnostic et de la therapie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69737293D1 true DE69737293D1 (de) | 2007-03-15 |
| DE69737293T2 DE69737293T2 (de) | 2007-06-21 |
Family
ID=9498426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69737293T Expired - Lifetime DE69737293T2 (de) | 1996-12-06 | 1997-12-05 | Nukleotidsequenz, die für eine flavinmonooxygenase kodiert, das korrespondierende protein, sowie deren verwendungen in diagnostik und therapie |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US6551792B1 (de) |
| EP (1) | EP0941341B1 (de) |
| JP (1) | JP4062638B2 (de) |
| AT (1) | ATE352635T1 (de) |
| AU (1) | AU746293B2 (de) |
| CA (1) | CA2274011A1 (de) |
| CY (1) | CY2605B2 (de) |
| DE (1) | DE69737293T2 (de) |
| DK (1) | DK0941341T3 (de) |
| ES (1) | ES2279552T3 (de) |
| FR (1) | FR2756845B1 (de) |
| PT (1) | PT941341E (de) |
| WO (1) | WO1998024914A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2756845B1 (fr) | 1996-12-06 | 1999-02-26 | Genset Sa | Sequence nucleotidique codant pour une flavine monooxygenase , proteine correspondante et composition destinee au diagnostic et a la therapie du glaucome |
| AU7500800A (en) * | 1999-09-30 | 2001-04-30 | Mcgill University | Human fmo3 gene mutations and polymorphisms, and uses thereof |
| US6902890B1 (en) | 1999-11-04 | 2005-06-07 | Diadexus, Inc. | Method of diagnosing monitoring, staging, imaging and treating cancer |
| JP2002142765A (ja) * | 2000-07-14 | 2002-05-21 | Tosoh Corp | 新規ゲノム解析法 |
| AU2001276210A1 (en) | 2000-07-18 | 2002-01-30 | National Research Council Of Canada | Cloning, sequencing and expression of a comamonas cyclopentanone 1,2-monooxygenase-encoding gene in escherichia coli |
| EP1358353B1 (de) * | 2000-12-28 | 2007-06-20 | Epidauros Biotechnologie AG | Identifizierung von genetischen determinanten der polymorphen cyp3a5 expression |
| RU2730863C2 (ru) | 2015-09-11 | 2020-08-26 | Новозимс Биоаг А/С | Стабильные композиции с инокулянтом и способы их получения |
| WO2018118740A1 (en) | 2016-12-20 | 2018-06-28 | Novozymes Bioag A/S | Stable inoculant compositions and methods for producing same |
| CN111973736B (zh) * | 2020-08-17 | 2026-04-17 | 浙江大学 | 含黄素单氧化酶2在制备非酒精性脂肪肝病治疗药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4305696A1 (de) * | 1993-02-25 | 1994-09-01 | Hoechst Ag | Nachweisverfahren zur Identifizierung von Inhibitoren |
| US5728676A (en) * | 1994-09-08 | 1998-03-17 | Ciba-Geigy Corporation | Use of insulin-like growth factors I and II for inhibition of inflammatory response |
| JPH08140674A (ja) * | 1994-11-18 | 1996-06-04 | Sumitomo Chem Co Ltd | ヒトフラビン含有モノオキシゲナーゼ |
| FR2756845B1 (fr) | 1996-12-06 | 1999-02-26 | Genset Sa | Sequence nucleotidique codant pour une flavine monooxygenase , proteine correspondante et composition destinee au diagnostic et a la therapie du glaucome |
-
1996
- 1996-12-06 FR FR9615032A patent/FR2756845B1/fr not_active Expired - Fee Related
-
1997
- 1997-12-05 DK DK97950244T patent/DK0941341T3/da active
- 1997-12-05 AT AT97950244T patent/ATE352635T1/de active
- 1997-12-05 ES ES97950244T patent/ES2279552T3/es not_active Expired - Lifetime
- 1997-12-05 AU AU53271/98A patent/AU746293B2/en not_active Ceased
- 1997-12-05 CA CA002274011A patent/CA2274011A1/fr not_active Abandoned
- 1997-12-05 WO PCT/FR1997/002226 patent/WO1998024914A1/fr not_active Ceased
- 1997-12-05 EP EP97950244A patent/EP0941341B1/de not_active Expired - Lifetime
- 1997-12-05 PT PT97950244T patent/PT941341E/pt unknown
- 1997-12-05 JP JP52530098A patent/JP4062638B2/ja not_active Expired - Fee Related
- 1997-12-05 DE DE69737293T patent/DE69737293T2/de not_active Expired - Lifetime
-
1999
- 1999-06-04 US US09/326,480 patent/US6551792B1/en not_active Expired - Fee Related
-
2003
- 2003-02-25 US US10/374,228 patent/US7037709B2/en not_active Expired - Fee Related
-
2006
- 2006-03-17 US US11/378,840 patent/US20060154295A1/en not_active Abandoned
-
2007
- 2007-03-22 CY CY0700006A patent/CY2605B2/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2756845A1 (fr) | 1998-06-12 |
| US6551792B1 (en) | 2003-04-22 |
| DE69737293T2 (de) | 2007-06-21 |
| WO1998024914A1 (fr) | 1998-06-11 |
| EP0941341A1 (de) | 1999-09-15 |
| EP0941341B1 (de) | 2007-01-24 |
| US20060154295A1 (en) | 2006-07-13 |
| AU746293B2 (en) | 2002-04-18 |
| AU5327198A (en) | 1998-06-29 |
| CA2274011A1 (fr) | 1998-06-11 |
| US20030203463A1 (en) | 2003-10-30 |
| FR2756845B1 (fr) | 1999-02-26 |
| JP4062638B2 (ja) | 2008-03-19 |
| DK0941341T3 (da) | 2007-03-19 |
| US7037709B2 (en) | 2006-05-02 |
| PT941341E (pt) | 2007-02-28 |
| CY2605B2 (en) | 2010-04-28 |
| ES2279552T3 (es) | 2007-08-16 |
| JP2001505430A (ja) | 2001-04-24 |
| ATE352635T1 (de) | 2007-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Todorov et al. | Characterization of a cancer cachectic factor | |
| Sanger | The chemistry of insulin | |
| DE68906077T2 (de) | Interleukin-1-inhibitoren. | |
| ATE182901T1 (de) | Für androgen-rezeptor-protein kodierende dna | |
| KR970701776A (ko) | 형질전환 성장 인자 알파 에이치1(Transforming growth factor alpha H1) | |
| DE69735375D1 (de) | Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung | |
| EP1484339A3 (de) | Kallikreinhemmende "Kunitz-Domäne"Proteine dafür kodierende Nukleinsäure | |
| DK1005540T3 (da) | IKK-beta-proteiner, nukleinsyrer og fremgangsmåder | |
| TR199802252T2 (xx) | N�ral ve renal geli�menin uyar�lmas� i�in ret ligand� (RetL) | |
| ATE170192T1 (de) | Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden | |
| NZ279963A (en) | Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946 | |
| DE59101889D1 (de) | Variante cd44-oberflächenproteine, diese kodierende dna-sequenzen, antikörper gegen diese proteine sowie ihre verwendung in der diagnostik und therapie. | |
| IS2819B (is) | Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra | |
| ATE352635T1 (de) | Nukleotidsequenz, die für eine flavinmonooxygenase kodiert, das korrespondierende protein, sowie deren verwendungen in diagnostik und therapie | |
| DE69729954D1 (de) | Identifizierungsverfahren für Substanzen die an das Pyk2 Polypeptid binden | |
| ATE299182T1 (de) | Polynukleotide und polypeptide aus pathogenen mycobakterien und deren verwendung als diagnostika, impfstoffe und als ziel der chemotherapie | |
| NO982181L (no) | Type IX collagen og chimerer | |
| DE69128416T2 (de) | Fibronektin bindendes Peptid | |
| NO913129D0 (no) | Nytt trombolytisk middel. | |
| CA2099503A1 (en) | Synthetic alpha-l-iduronidase and genetic sequences encoding same | |
| EP1443055A3 (de) | Interleukine-21 und 22 | |
| DE69433902D1 (de) | Neuartige tyrosinkinase | |
| DK0870036T3 (da) | Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor | |
| PT990000E (pt) | Factor 3 de crescimento do tecido conjuntivo | |
| NO962596L (no) | Nytt tumorsupressorgen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |